Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
133 hedge funds and large institutions have $1.3B invested in Intra-Cellular Therapies Inc. in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 47 reducing their positions, and 24 closing their positions.
337% more capital invested
Capital invested by funds: $298M → $1.3B (+$1B)
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
6% more funds holding
Funds holding: 126 → 133 (+7)
23% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 47
53% less call options, than puts
Call options by funds: $260M | Put options by funds: $549M
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$23.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.6M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$7.05M |
| 4 |
VMI
VHCP Management III
New York
|
+$6.9M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.84M |
Top Sellers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$26.8M |
| 2 |
Millennium Management
New York
|
-$11.7M |
| 3 |
SC
Samlyn Capital
New York
|
-$11M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$8.11M |
| 5 |
ClearBridge Investments
New York
|
-$5.61M |
ITCI Hedge Fund Activity: Q4 2019 in Review
133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2019, worth a combined $1.3B — up 337% from $298M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ITCI positions and 24 closed out — a net gain of 7 holders — while 36 added to existing stakes and 47 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $23.5M. The largest seller was Wasatch Advisors, cutting an estimated $26.8M.
- 133 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2019, up from 126 in Q3 2019.
- Funds reported $1.3B of Intra-Cellular Therapies Inc. stock for Q4 2019, up 337% quarter-over-quarter.
- 31 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2019 and 24 closed out, a net change of +7 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2019 was Consonance Capital Management, an estimated $23.5M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2019 was Wasatch Advisors, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2019.